GGPS1 and chronic myelogenous leukemia, BCR-ABL1 positive: In this study induction of apoptosis in Molt-4 and Jurkat cells was observed, with effective concentration for 50% reduction in viability (EC50) of 15 (4.7–48) μM and 30 (14–64) μM in Molt-4 and Jurkat cells, respectively.53 A second study focusing on chronic myelogenous leukemia (CML) reported similar results with structurally related GGPPS inhibitors.